Investors pummel Brazil's Dasa for turmoil and sluggish Dx sales

Investors are pummeling one of Brazil's largest providers of medical diagnostics as the company struggles under management turmoil and sluggish sales, Bloomberg reports. Diagnosticos da America SA, or Dasa, endured a 24% drop in trading in São Paulo so far this year, according to the story. Why such a drastic drop? Concerns are growing as the company has worked its way through 7 different CEOs or CFOs so far this year, Raymond James analyst Guilherme Assis told Bloomberg. What would help alleviate the situation, the story explains, is for Dasa to develop a strategy to fuel growth as incomes rise in Brazil and more people migrate from the public health system to private providers. Story

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.